Color fundus autofluorescence to determine activity of macular neovascularization in age-related macular degeneration by Vujosevic, S. et al.
Article
Color Fundus Autofluorescence to Determine Activity of
Macular Neovascularization in Age-Related Macular
Degeneration
Stela Vujosevic1,2, Caterina Toma2, Valentina Sarao3,4, Daniele Veritti3,
Marco Brambilla5, Andrea Muraca2, Stefano De Cillà2,6, Edoardo Villani1,7,
Paolo Nucci7, and Paolo Lanzetta3,4
1 Eye Clinic IRCCS MultiMedica, Milan, Italy
2 University Hospital Maggiore della Carità, Eye Clinic, Novara, Italy
3 Department of Medicine-Ophthalmology, University of Udine, Udine, Italy
4 Istituto Europeo di Microchirurgia Oculare-IEMO, Udine, Italy
5 Department of Medical Physics, University Hospital Maggiore Della Carità, Novara, Italy
6 Department of Health Sciences, University East Piedmont “A. Avogadro,”Novara, Italy
7 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
Correspondence: Stela Vujosevic,
Eye Clinic IRCCS MultiMedica, Via
San Vittore 12, 20123 Milan, Italy.
e-mail: stela.vujosevic@gmail.com;
stela.vujosevic@unimi.it
Received: July 22, 2020
Accepted: January 10, 2021






Citation: Vujosevic S, Toma C, Sarao
V, Veritti D, Brambilla M, Muraca A,
De Cillà S, Villani E, Nucci P, Lanzetta
P. Color fundus autofluorescence to
determine activity of macular
neovascularization in age-related
macular degeneration. Trans Vis Sci
Tech. 2021;10(2):33,
https://doi.org/10.1167/tvst.10.2.33
Purpose: To evaluate with color fundus autofluorescence (FAF) different lesion compo-
nents of macular neovascularization (MNV) secondary to age-related macular degener-
ation (AMD) and to assess its activity.
Methods: In total, 137 eyes (102 patients) with MNV underwent a complete eye exami-
nation, including color fundus photography, optical coherence tomography (OCT), OCT
angiography, and confocal color FAF, with an excitation wavelength at 450 nm. Each
image was imported into a custom-image analysis software for quantitative estimation
of emission wavelength and green and red emission fluorescence (GEFC/REFC) inten-
sity, considering both single components of neovascular AMD and different MNV types
(type 1 and type 2 MNV, active and inactive MNV).
Results: Subretinal fluid (SRF) had significantly higher values of GEFC (P = 0.008 and
P = 0.0004) and REFC intensity (P = 0.005 and P = 0.0003) versus fibrosis and atrophy.
The emission wavelength from SRF was lower compared to atrophy (P = 0.024) but
not to fibrosis (P = 0.46). No significant differences were detected between type 1 and
2 MNV. Considering active versus inactive MNVs, a difference was detected for all evalu-
ated parameters (P< 0.001). Mean FAF wavelength of both MNV with SRF and intrareti-
nal fluid (IRF) was lower versus inactive MNV (P < 0.001 and P = 0.005). MNV with SRF
(P < 0.001) had higher values of GEFC and REFC versus inactive MNV (P < 0.001). MNV
with IRF had higher values of GEFC versus inactive MNV (P = 0.05).
Conclusions: Quantitative color FAF can differentiate active versus inactive MNV,
whereas no differences were found between type 1 and type 2 MNV. If these data can
be further confirmed, color FAF may be useful for automatic detection of active MNV in
AMD and as a guide for treatment.
Translational Relevance: Automatic quantitative evaluation of green and red emission
components of FAF in AMD can help determine the activity of MNV and guide the
treatment.
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Introduction
Neovascular age-related macular degeneration
(nAMD) remains the most common cause of visual
impairment in patients with age-related macular
degeneration (AMD) despite the introduction of anti-
vascular endothelial growth factor (VEGF) treatment.1
Diagnosis of nAMD is made mostly by fundus exami-
nation and multimodal imaging, which led recently
to a new terminology of nAMD, namely, macular
neovascularization (MNV) secondary to AMD.2
Conventional fundus autofluorescence (FAF) (488
nm) and near-infrared autofluorescence have been used
in nAMD for evaluation of the status of the retinal
pigment epithelium (RPE) in MNV with fluid and
also for the evaluation of new development or enlarge-
ment of preexisting atrophy during the treatment.1,3–9
Moreover, FAF can be used as a prognostic param-
eter in nAMD, as a predominantly preserved FAF
pattern in the macula showed better visual acuity (VA)
outcome.5 Using conventional confocal blue light at
488 nm, detected FAF is mostly due to the lipofuscin
in the RPE. Lipofuscin is a by-product of phagocyto-
sis of the photoreceptor outer segments and accumu-
lates in the RPE with age, contributing to the patho-
genesis of AMD.10 Lipofuscin has a broad spectrum
of excitation (300–600 nm) and emission (480–800
nm) wavelengths. There are more than 10 fluorophores
identified so far that may be responsible for the
FAF signal at different wavelengths. Besides lipofus-
cin, these include lipofuscin-like lipopigments, vitamin
A (retinols and carotenoids), protoporphyrin IX and
porphyrin derivates, fatty acids (accumulated lipids),
flavins (coenzymes of key enzymes in redox reactions),
nicotinamide adenine dinucleotide phosphate, colla-
gen/elastin (extracellular fibrous proteins), cytoker-
atins (intracellular fibrous proteins), and aromatic
amino acids (phenylalanine, tyrosine, and triptophane;
functional proteins).11 Thus, fluorescence of the ocular
fundus may be related to various pathologic processes,
including also the advanced glycation end products
(AGEs), and may be regarded as a general feature of
aging and disease progression.12,13
The possibility to discriminate different
fluorophores and lesion components may help in
the diagnosis and management of nAMD. Recently, a
novel short-wavelength confocal blue autofluorescence
system has been available, using a 450-nm excita-
tion wavelength. This instrument has a possibility to
obtain the so-called color FAF that uses two different
emission spectral channels, the shorter component
(green, at 510–560 nm) and the longer one (red, at
560–700 nm). In this way, there is a potential to
isolate minor fluorophores that otherwise would
be overwhelmed by the lipofuscin.14 There are very
limited data in the literature on the use of color FAF
in geographic atrophy.14,15 No data are currently avail-
able on the use of color FAF in nAMD, especially in
the quantitative estimation of green and red emission
spectra for assessing the activity of MNV.
The aim of this study was to quantitatively evalu-
ate different lesion components in the context of MNV
secondary to AMD to determine if color FAF can be
useful to discern between active and inactiveMNV and
may be used noninvasively as adjunctive information
when deciding treatment.
Materials and Methods
Patients and Study Design
In this prospective, observational, cross-sectional
case evaluation, we consecutively enrolled 137 eyes (102
patients) affected by macular nAMD, both active and
inactive, who presented at the Medical Retina Service
of the Eye Clinic (University Hospital Maggiore della
Carità, Novara, Italy) and at the Ambulatory Surgery
Center Istituto Europeo di Microchirugia Oculare-
IEMO, Udine, Italy, from September 1 to 30, 2019.
Diagnosis and assessment of disease activity were
based on clinical examination performed by expert
retinal specialists (SV and VS) and confirmed by multi-
modal retinal imaging.
Inclusion criteria were diagnosis of unilateral or
bilateral macular nAMD with and without signs of
active disease, both treatment naive and previously
treated with anti-VEGF, and pseudophakia or only
mild cataract (not precluding good-quality imaging).
Exclusion criteria were any maculopathy other than
macular nAMD, previous vitreoretinal surgery, use of
drugs that could interfere with macular function (e.g.,
hydroxychloroquine, tamoxifen), and poor quality of
imaging due to significant media opacity or poor
fixation. Active disease was defined as the presence of
exudation at the time of clinical evaluation confirmed
by detection of subretinal and/or intraretinal fluid on
OCT.
Anamnestic data concerning disease history were
carefully collected. Each patient underwent a complete
eye examination, including best-corrected visual acuity
(BCVA), determined at 4 m with standard Early Treat-
ment Diabetic Retinopathy Study (ETDRS) charts,
intraocular pressure measurement, dilated fundus
examination with a 90-D lens, and noninvasive
multimodal imaging with color fundus photogra-
phy (CFP), swept-source OCT (SS-OCT) and OCT
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angiography (OCT-A), and FAF. Fluorescein angiog-
raphy was performed in case of first diagnosis of
nAMD, as per usual clinical practice.
The study adhered to the tenets of the Declara-
tion of Helsinki and was approved by the institu-
tional Ethics Committee; each patient signed a written
informed consent prior to image acquisition.
Imaging
SS-OCT
SS-OCT and SS-OCT-A scans were acquired using
DRI SS-OCT/OCT-A Triton plus (Topcon Europe
Medical BV, Capelle aan den IJssel, The Netherlands).
The acquisition protocol included 9-mm radial and
five line-cross OCT scans centered on the fovea, as
well as a three-dimensional 4.5-mm × 4.5-mm OCT-
A map of the macula. OCT and OCT-A images were
used to define the diagnosis of type 1 and type 2
MNV according to the new classification proposed by
Spaide et al.2 Moreover, OCT B-scans were carefully
examined to detect signs of MNV activity, defined
as the presence of intraretinal and/or subretinal fluid
(intraretinal cysts, serous or hemorrhagic detachment
of the neuroretina)16,17 and serous, hemorrhagic, or
fibrovascular pigment epithelium detachment (PED).
OCT-A en-face images were used to confirm the
presence and topographic colocalization of MNV
when evaluating FAF images.
Color Fundus Photography and Fundus Autofluore-
scence
CFPs and FAF images were acquired using a confo-
cal light-emitting diode (LED) fundus imaging system
(EIDON; CenterVue, Padua, Italy). The confocal LED
blue-light FAF device has an excitation wavelength
between 440 and 475 nm (peak at 450 nm) and
emission detection between 500 and 750 nm. In this
device, the full-emission spectrum is detected on a color
sensor, providing so-called color FAF images, consist-
ing of only the red (range 560–700 nm) and green
(range 500–560 nm) emission fluorescence components
(REFCs/GEFCs). The device is fully automated. With
a single exposure, a 60-degree (horizontal) × 55-degree
(vertical) image (resolution 3680 × 3288 pixels) of
the posterior pole was acquired. Two different graders
(CT and VS) carefully and independently reviewed all
images to check for good quality prior to further analy-
ses, since it could significantly influence the results.
Moreover, they identified and localized each compo-
nent present in the context of the macular lesion by
comparing color FAF images with corresponding true
color photos and OCT and OCT-A scans. Finally, the
two graders compared the gradings, and in case of
disagreement, one grader (SV) gave the final adjudi-
cation on the quality of images and identification of
single-lesion components.
In particular, the following lesion components were
considered: MNV, hemorrhage (He), subretinal fluid
(SRF), intraretinal fluid (IRF), PED, fibrosis, and
atrophy.
Color FAF Image Analysis
For each eye, the original color FAF image was
exported and imported into the custom-made image
analysis software “FAF Color Segmentation Tool”
purposely designed by the manufacturer for the
quantitative evaluation of these images, as previously
described.18 This software is able to separately and
quantitatively measure the long-wavelength (red-R)
and short-wavelength (green-G) components of the
emission spectrum (emission fluorescence components,
REFCs and GEFCs) of each pixel of the image. The
software provides an estimation of the wavelength by
means of an exponential model based on the propor-
tion of GEFCs and REFCs. Fluorescence intensity
and emission wavelengths of each pixel of the image
are displayed in a two-dimensional xy graph (segment
graph), where emission wavelength is reported on the
x-axis and intensity on the y-axis. A second xy-graph
(explore graph) quantifies the intensity of the REFC
(x-axis) and of the GEFC (y-axis) for each pixel of the
image.
Since the software is able to elaborate data of
fluorescence for each pixel but not differentiate between
different lesion components contributing to the final
fluorescence of a specific pixel, only regions where the
single component was clearly identifiable were consid-
ered in the final analysis. IRF with cystoid spaces
was excluded from the analysis of single-lesion signal
because it could not be clearly isolated from the other
components. All the imageswere carefully evaluated for
the presence of any artifacts (i.e., eye movement, iris
blockage, etc.), and in such a case, they were manually
excluded from the data set.
To achieve more reliable results for each lesion,
data of fluorescence were recorded at four different
sites (pixel squares, each corresponding to approxi-
mately 5 × 5 μm2), and a mean of these four values
was computed (Fig. 1). All images were rechecked by
one author (SV) to ensure correct evaluation of single
lesions.
After this first step, a second analysis was performed
differentiating active from inactive MNV and type 1
from type 2 MNV, as previously described. Active
MNV was further analyzed based on the presence of
SRF or IRF colocalizing with the MNV. Eyes with
hemorrhages masquerading the MNV were excluded
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Figure 1. Example image showing the methodology used for
analysis. (A) True-color fundus photography showing the presence
of circular areas of chorioretinal atrophy (in the black box) in
the context of neovascular AMD. (B) Corresponding color FAF
image. (C) Detail of color FAF image showing the four analyzed
sites (highlighted by white asterisks). The image analysis software
recorded the following values for the four sites: site 1 wavelength
580.6, GEFC 22, REFC 24; site 2 wavelength 580.9, GEFC 21, REFC
25; site 3 wavelength 577.1, GEFC 24.5, REFC 24.5; site 4 wavelength
579.6, GEFC 21, REFC 20.5.
from this analysis. Data of fluorescence (fluorescence
intensity and emission wavelength, intensity of the
REFCs andGEFCs) were recorded at 10 different sites,
and a mean of these 10 values was computed.
Statistical Analyses
The means of the experimental groups were
reported as arithmetic mean (standard deviation) and
median (range) for continuous variables in the text
and tables. Differences in the means of the depen-
dent variables (red-R, green-G, intensity, and emission
wavelengths) were studied with analysis of variance
(ANOVA) methods.
In the first analysis, a one-way ANOVA was
used to assess the impact of the different types of
lesions (SRF, fibrosis, and atrophy) on the dependent
variables.
A two-way ANOVA with principal effects was
employed in the second analysis. The first two-level
factor was MNV type. The second three-level factor
was the status (active or inactive) of MNV. Active
MNVs were further evaluated based on the presence of
SRF versus IRF. When a principal effect was found, a
post hoc Scheffé test was used to identify the sources
of variability.
Analysis was performed with Statistica version 6.0
(StatSoft, Tulsa, OK, USA) using a two-sided type I
error rate of P = 0.05.
Results
Of 137 eyes (102 patients) initially recruited in
the study, 97 eyes (80 patients) were included in the
final analysis. Twenty-six eyes were excluded due to
poor quality of FAF imaging (due to motion artifacts,
iris blockage, or media opacities) and 14 eyes due to
advanced nAMD (large disciform scars) with complete
subversion of macular morphology with impossibility
to identify single components of lesions.
Mean age was 79.5 ± 8.4 years (range, 50–96 years);
54 patients were women and 26 were men. All patients
were of Caucasian ethnicity. Twenty-one eyes had
treatment-naive nAMD (13 eyes with type 1 MNV, 8
eyes with type 2 MNV) and 76 eyes had previously
treated nAMD (mean number of previous anti-VEGF
injections was 8.6± 5.8); 57 eyes had active nAMDand
40 eyes inactive nAMD on clinical examination and
OCT. Mean BCVA was 75.6 ± 16.8 ETDRS letters in
eyes with active MNV and 59.1 ± 20.2 ETDRS letters
in eyes with inactive MNV.
Mean values, median, and range of FAFwavelength
and intensity of GEFCs andREFCs of different evalu-
ated lesions (MNV, He, SRF, PED, fibrosis, atrophy)
are reported in Table 1.
Compared to fibrosis and atrophy, SRF had signif-
icantly higher values of GEFC intensity (P = 0.008
and P = 0.0004) and REFC intensity (P = 0.005
and P = 0.0003). The emission wavelength from all
the evaluated lesions was within the yellow wavelength
spectrum.However, the emissionwavelength fromSRF
was significantly lower compared to atrophy (P =
0.024) but not to fibrosis (P = 0.46). No significant
differences were detected between fibrosis and atrophy
for the analyzed parameters.
Mean values, median, and range of FAFwavelength
and intensity of GEFCs and REFCs of the differ-
ent evaluated MNV types (type 1 and type 2 MNV,
MNVwith IRF or SRF, inactiveMNV) are reported in
Table 2.
As for comparison between type 1 MNV and type
2 MNV, no significant differences were detected for
the analyzed parameters (P = 0.75). Therefore, for
subsequent analyses between active and inactiveMNV,
type 1 and type 2 MNV were considered together.
Considering all active MNVs together versus
inactive MNV, a significant difference was detected
for all evaluated parameters (P < 0.001). Mean FAF
wavelength of both MNV with SRF and IRF was
significantly lower than that of inactive MNV (P <
0.001 and P = 0.005, respectively). No significant
differences were detected for mean FAF wavelength
between MNV with SRF and IRF. MNV with SRF
had significantly higher values of GEFC and REFC
intensity compared to MNV with IRF (P = 0.002 and
P< 0.001, respectively) and inactiveMNV (P< 0.001).
MNV with IRF had a higher mean value of GEFC
versus inactive MNV (P = 0.05), and an increasing
Downloaded from tvst.arvojournals.org on 04/27/2021
Color Fundus Autofluorescence in Neovascular AMD TVST | February 2021 | Vol. 10 | No. 2 | Article 33 | 5
Table 1. FAF Wavelength and GEFC and REFC Intensity of Different Lesion Components in Macular Neovascular-
ization
Lesion Wavelength GEFC Intensity REFC Intensity
MNV
Mean ± SD 577.3 ± 4.66 57.24 ± 34.24 63.89 ±31.41
Median 577.43 43.13 57.75
Range 567.9–590.98 1–124 18–134
He
Mean ± SD 584.72 ± 8.21 19.27 ± 18.86 26.6 ± 18.13
Median 585.45 12.38 12.38
Range 573.5–600 0–63 0–63
SRF
Mean ± SD 576.92 ± 1.83 95.98 ± 64.66 105.49 ± 67.17
Median 577.06 69.75 112.0
Range 573.3–579.3 13.75–238.25 16.0–255.0
PED
Mean ± SD 577.08 ± 3.71 63.29 ± 43.47 68.96 ± 41.24
Median 578.24 47.75 56.25
Range 572.35–584.55 15.5–182.25 19.25–180.0
Fibrosis
Mean ± SD 580.2 ± 8.0 42.5 ± 41.2 49.8 ± 38.0
Median 577.38 37.5 41.5
Range 568.33–594.9 1–164 5–132.75
Atrophy
Mean ± SD 585.2 ± 8.0 17.9 ± 18.7 26.6 ± 17.4
Median 574.08 29.5 28.75
Range 579.1–594.1 2–116.75 5–98.250
trend was detected for REFC intensity versus inactive
MNV (Table 3 and Figs. 2–4).
Of 16 eyes with active MNV and IRF on OCT, 9
(56.25%) had signs of fibrosis, 3 (18.75%) had outer
retina and RPE atrophy, and only 4 eyes (25%) had
also SRF, in a different location of MNV and IRF.
Eyes with activeMNVand IRF had lowermean BCVA
(66.43 ± 20.51 letters) versus eyes with active MNV
and SRF (79.69 ± 13.43 letters), P = 0.07.
Discussion
In the present study, we report on quantitatively
determined color FAF data in nAMD. Eyes with
both active and inactive nAMD lesions (type 1 and 2
MNV), as determined by clinical evaluation, OCT, and
OCT-A, were analyzed. Different single components,
such as SRF, intra/subretinal He, PED, subretinal
fibrosis, and atrophy, were separately evaluated.
The autofluorescence of the fundus is a complex
phenomenon and depends on different fluorophores.
The fluorescence from the lipofuscin and N-
retinylidene-N-retinylethanolamine (A2E) is mostly
responsible for the FAF intensity in the longer-
wavelength emission range (mostly the red spectrum,
between 580 and 700 nm). However, all other minor
fluorophores contribute mostly to the FAF inten-
sity in the shorter-wavelength emission range (green
spectrum, above 500 nm to 560 nm). These minor
fluorophores may be better excited at a shorter, blue
wavelength.14 These include, besides A2E, the oxidized
fluorescent form flavin adenine dinucleotide (FAD)
of the redox pair FAD–FADH2, important for evalu-
ation of the metabolic state of the photoreceptor’s
inner-segment mitochondria (with single maximum-
emission FAF at 524 nm); AGEs (the extracellular
material, accumulating in older patients in soft drusen,
basal laminar deposits, and RPE cells and considered
biomarkers of aging)19,20; and, in limited amount,
collagen 2 (emission at 508 nm), due to the reduced
fluorescence intensity down to 20% at a 450-nm
wavelength excitation.9,21
In the present study, all the considered lesion
components had the overlapping spectrum of mean
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Table 2. FAF Wavelength and GEFC and REFC Intensity of Different MNV Types
MNV Type Wavelength GEFC Intensity REFC Intensity
MNV1 active + IRF (10)
Mean ± SD 575.7 ± 4.45 59.08 ± 29.30 58.75 ± 27.40
Median 576.17 53.35 52
Range 566.34–581.03 12.1–97.3 15.8–107.5
MNV1 active + SRF (14)
Mean ± SD 576.5 ± 3.0 88.89 ± 43.14 95.41 ± 40.43
Median 577.38 92.9 94.8
Range 571.61–581.18 24.2–150.7 26.2–148.3
MNV1 inactive (22)
Mean ± SD 579.76 ± 5.99 31.54 ± 21.95 35.42 ± 21.53
Median 578.95 22.9 27.65
Range 571.69–593.55 8.2–77.7 10.8–89.7
MNV2 active + IRF (6)
Mean ± SD 576.32 ± 1.83 56.15 ± 42.69 57.37 ± 36.64
Median 576.23 42.10 44.85
Range 573.57–579.18 16.3–129.7 21.9–118.8
MNV2 active + SRF (18)
Mean ± SD 575.53 ± 2.22 104.97 ± 50.73 106.86 ± 48.41
Median 575.65 129.4 125.4
Range 570.34–578.87 40.3–182.2 41.6–170.4
MNV2 inactive (18)
Mean ± SD 582.59 ± 7.33 32.29 ± 26.38 37.45 ± 24.66
Median 580.12 19.4 24.6
Range 569.99–596.1 4.4–86.9 9–86.8
Table 3. Comparison between Active and Inactive
MNVs
MNV Type Wavelength GEFC Intensity REFC Intensity
Active 575.9 ± 2.9 84.6 ± 47.0 87.3 ± 45.2
+ SRF 575.9 ± 2.6a 97.9 ± 47.5 101.8 ± 44.8
+ IRF 575.9 ± 3.6b 58.0 ± 33.5c,d 58.2 ± 30.0e
Inactive 581.0 ± 6.7 31.9 ± 23.7e 36.3 ± 22.7e
P valuef <0.001 <0.001 <0.001
aComparison versus inactive MNVs: Scheffé’s test, P <
0.001.
bComparison versus inactive MNVs: Scheffé’s test, P =
0.005.
cComparison versus inactive MNVs: Scheffé’s test, P= 0.05.
dComparison versus active MNVs + SRF: Scheffé’s test, P =
0.002.
eComparison versus active MNVs + SRF: Scheffé’s test, P <
0.001.
fTwo-way ANOVA analyses: comparison between patients
with active and inactive MNV. Statistical significance was set
at P = 0.05. Values are reported as mean ± SD.
FAF emission in the range between 566 and 600
nm when excited by the short-wavelength blue light
(at 450 nm). The only difference found was between
atrophy and SRF, with SRF emitting at a shorter
wavelength.
However, when evaluating quantitative data on FAF
obtained automatically by the current software, one
should bear in mind that the FAF value is the weighted
average emission value of that wavelength (as stated
by the manufacturer). Thus, it would mean that a
specific FAF emission wavelength value may be due to
a single emitted wavelength from the lesion or to two
different wavelengths but with equal GEFC and REFC
intensity. Therefore, this value needs to be integrated
with clinical (morphologic/functional/metabolic) data
of the patient to bemore appropriately interpreted. For
example, in the present study, SRF had much higher
intensity in the REFCs versus GEFCs, whereas the
mean FAF wavelength was 576.92 ± 1.83 nm, similar
to other lesion components. Therefore, the red emission
fluorophores (such as the lipofuscin and the A2E)
contribute more than the fluorophores in the green
wavelength spectrum within the SRF for the similar
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Figure2. Right eyeof a 78-year-old femalepatientwith activeMNV
secondary to AMD. (A) True-color fundus photography showing a
yellowish central area corresponding to MNV with subretinal fluid
expanding in particular inferiorly to the fovea. (B) Color FAF showing
a high intensity of the emitting components at the site of SRF (REFC
intensity 80, GEFC intensity 69.75) at a mean wavelength of 576.96
nm (indicated by black arrows). (C) OCT vertical B-scan centered on
the fovea showing a subfoveal active MNV as demonstrated by the
presence of SRF adjacent to the MNV. (D, E) OCT-A slabs showing a
neovascular net interesting both the outer retina (D) and choriocap-
illaris (E).
Figure 3. Left eye of an 85-year-old female patient affected by
active MNV secondary to AMD. (A) True-color fundus photogra-
phy showing a whitish-yellowish central area. (B) Color FAF showing
irregular areas of altered autofluorescence surrounding the fovea
(indicated by black arrow), with higher intensity of the quantitatively
evaluated emitting components in red (REFC intensity 71.9, GEFC
intensity 57.4) at a mean wavelength of 579.09 nm. (C) OCT verti-
cal B-scan centered on the fovea showing thickened subfoveal outer
retina layers with overlying small intraretinal cysts and initial outer
retina tubulations; no SRF is detectable. (D, E) OCT-A of the outer
retina (D) and choriocapillaris (E) slabs showing a neovascular net
interesting both slabs but with larger size of the MNV detected at
the choriocapillaris.
Figure 4. Right eye of a 77-year-old female patient affected by
inactiveMNV secondary to AMD. (A) True-color fundus photography
showing presence of a fibrovascular lesion. (B) Color FAF showing
reduced intensity of the quantitatively evaluated emitting autoflu-
orescence components (REFC intensity 24.1, GEFC intensity 22.5)
at a mean wavelength of 588.17 nm (indicated by black arrows).
(C) OCT horizontal B-scan centered on the fovea showing thickened
subfoveal outer retina layers with no signs of MNV activity (SRF or
IRF) and perifoveal outer retina tubulations. (D, E) OCT-A of the outer
retina (D) and choriocapillaris (E) slabs showing a large neovascular
net interesting both slabs.
final FAF emission wavelength as for the other detected
components in nAMD. Moreover, SRF had much
higher fluorescence emission intensities than atrophy
and subretinal fibrosis. The significance of this finding
is that many more fluorophores are present/excited in
SRF versus atrophy and fibrosis. In fact, the latter
lesions are characterized by hypo-autofluorescence
with conventional blue FAF (at 488 nm) due to the
loss of the RPE cells and decrease in lipofuscin
granules.22 However, in the present study, some green
and red emission fluorophores were still detected in
both atrophy and subretinal fibrosis. Although the
present data cannot be directly compared to other
studies, due to different methodology of FAF evalu-
ation, our data are in line with data documented
by Borrelli et al.,14 who evaluated the presence and
pattern of GEFC signal in 25 eyes with atrophic AMD,
applying a custom-made image-processing algorithm
in which the REFCwas subtracted and only the GEFC
was evaluated within the areas of macular atrophy.
The authors concluded that GEFC signal was due
to the presence of hyperreflective material overlying
Bruch’s membrane (either residual sub-RPE deposits
or regressing drusen).14,23 In a different study on
atrophic AMD (and no signs of present or pastMNV),
the authors also reported a high capability of this new
FAF device to accurately detect the site and size of
atrophic lesions (after the isolation of the REFC).15
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More recently, the same group further validated the use
of color FAF in a healthy population and confirmed
that the quantitative evaluation of GEFC has high
reliability and repeatability, suggesting its potential
usefulness in assessing the retinal metabolic status in
different diseases such as AMD and diabetes.24
The importance of discriminating different
fluorophores may be useful for functional evalua-
tion of metabolic alterations of the retina during
AMD. Fundus structures that can produce the FAF
include the RPE (with lipofuscin granules), Bruch’s
membrane, and the sub-RPE deposits (drusen).22
Using a spectrophotometric detector with a scanning
laser confocal microscope, Marmorstein et al.22
documented that Bruch’s membrane and sub-RPE
deposits were excited by overlapping spectra in the
blue light and ultraviolet light, and the emission
fluorescence was detected in the blue-green range at
higher intensities in human donor eyes withAMD than
in age-matched control eyes. In fact, histologic data
confirmed that Bruch’s membrane is formed by five
layers: RPE–basal lamina (BL), inner collagenous layer
called the sub-RPE–basal lamina space, elastic layer,
outer collagenous layer, and choriocapillaris-BL.25
Therefore, certain contributions from the connec-
tive tissue (collagen/elastin) to the FAF in Bruch’s
membrane cannot be excluded.19,25
AGEs may play an important role in aging and
neovascularization.20 The progressive buildup of these
compounds may alter the structure and function of
proteins and may also contribute to the pathology of
metabolic diseases, such as diabetes, atherosclerosis,
and oxidative stress and inflammation associated with
neurodegenerative diseases of aging.19 AGEs stimulate
VEGF expression in cultured and in vivo RPE cells,
induce endothelial cells to secreteVEGF, and have an in
vitro angiogenic effect; therefore, the accumulation of
AGEs in soft drusen, basal laminar deposits, and RPE
cells may lead to overexpression of VEGF, transform-
ing growth factor-beta (TGFb), and platelet-derived
growth factor (PDGF); development of nAMD; and
fibrosis.20,26–29
When evaluating different types of MNV (type
1 and type 2), no differences in FAF parameters
were observed. Significant differences were found when
comparing active versus inactive MNV. Active MNVs
were considered those with subretinal or intrareti-
nal fluid on OCT, which is commonly used in clini-
cal practice to guide treatment decisions, whereas the
use of fluorescein angiography has decreased signif-
icantly.16,17,30 The differences included lower mean
FAF wavelengths and higher intensities of both green
and red emission components in active versus inactive
MNV. Especially active MNV with SRF had the
highest values in both green and red emission spectra.
When we separately evaluated active MNV with SRF
versusMNVwith IRF, we noticed thatMNVwith IRF
had more signs of chronicity, including fibrosis and
outer retina and RPE atrophy on OCT, and a trend to
lower BCVA. This negative impact of IRF (cysts) on
BCVA versus SRF was also reported in the Compar-
ison of AMD Treatments Trials (CATT) trial, proba-
bly due to apoptotic and necrotic cell death, visible on
OCT as small intraretinal cysts.31 Therefore, the values
of GEFCs and REFCs were lower than in MNV with
SRF with less chronic disease. These quantitative data
obtained with color FAF can be considered in line with
data obtained with standard blue (488-nm) FAF in
neovascular AMD. Whereas an increased pattern of
FAF corresponded well with SRF and the edges of
the choroidal neovascularization (CNV), indicating a
significant accumulation of lipofuscin caused by the
compensatory proliferation of RPE cells proximal to
CNV when disease progresses,32 and just in some cases
with drusen, a decreased FAF pattern corresponded to
fibrovascular/disciform scar, macular atrophy, blood,
pigmentary RPE changes, and, in one-third of cases,
active MNV.4,33–36 McBain et al.6 reported reduced
FAF in 90% of eyes with classic CNV (above the
RPE, type 2 MNV), whereas in occult CNV (beneath
the RPE, type 1 MNV), areas of increased FAF were
present, clinically corresponding to SRF. The origin of
the increased FAF signal was explained as an increased
content in RPE lipofuscin secondary to increased outer
segment shedding at sites of chronic neurosensory
retinal detachment.37,38 The decreased FAF (488 nm)
documented in classic CNV could not be distinguished
from decreased FAF due to macular atrophy, whereas
in color FAF, these lesions had very distinct parame-
ters (Tables 1, 2). Moreover, color FAF allows one to
separately detect fluorescence deriving also fromminor
fluorophores and, with the use of the specific software,
to separately quantify the emission intensity in the
green and red spectra. In this way, the activity of MNV
can be discerned from nonactive MNV, thus support-
ing a decision on the need for treatment. As quanti-
tative evaluation gives more precise data than qualita-
tive evaluation of color FAF, this method may offer
a possibility for automatic evaluation of the images
with an indication for treatment. This would need
to be confirmed in larger and possibly longitudinal
studies.
Besides the intrinsic limits of this new imaging
method (as previously described), the major limita-
tions of this study include the lack of longitudinal
data in order to evaluate correlation to visual acuity
outcomes, as well as the inclusion of patients with
pseudophakia or only with mild cataract. The 450-nm
Downloaded from tvst.arvojournals.org on 04/27/2021
Color Fundus Autofluorescence in Neovascular AMD TVST | February 2021 | Vol. 10 | No. 2 | Article 33 | 9
FAF is influenced by the lens condition; therefore, its
use in patients with more advanced cataracts and the
quality of obtained data need to be further evaluated.
However, the color FAF image is rather easily inter-
pretable, as it is actually a standard colored picture
that does not need any postprocessing in order to be
analyzed.
In conclusion, to our knowledge, this is the
first study to evaluate quantitative data obtained in
automatic fashion on color FAF in nAMD, evaluat-
ing separately green and red emission components of
the FAF. Significantly different data were documented
for active versus inactive MNV, while no differences
were found for type 1 versus type 2 MNV. If these data
can be further confirmed and validated in larger studies
comparing the color FAF to other imaging modali-
ties (in primis OCT, etc.), color FAF, with an easy and
fast single-shot image acquisition, may become a useful
tool for the automatic detection of activeMNVand for
guiding the treatment.
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